Synthetic Biologics Inc. [AMEX: SYN] plunged by -$0.05 during the normal trading session on Thursday and reaching a high of $0.50 during the day while it closed the day at $0.46. The company report on May 6, 2021 that Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results.
Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD.
Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase.
Synthetic Biologics Inc. stock has also loss -21.40% of its value over the past 7 days. However, SYN stock has declined by -43.55% in the 3 months of the year. Over the past six months meanwhile, it has gained 47.75% and gained 20.05% year-on date.
The market cap for SYN stock reached $59.62 million, with 129.66 million shares outstanding and 127.36 million shares in the current float. Compared to the average trading volume of 12.56M shares, SYN reached a trading volume of 4497936 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Synthetic Biologics Inc. [SYN]:
FBR & Co. have made an estimate for Synthetic Biologics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 06, 2017. While these analysts kept the previous recommendation, FBR Capital raised their target price from $10 to $9. The new note on the price target was released on May 06, 2016, representing the official price target for Synthetic Biologics Inc. stock. Previously, the target price had yet another raise to $10, while FBR Capital analysts kept a Outperform rating on SYN stock.
The Average True Range (ATR) for Synthetic Biologics Inc. is set at 0.05
SYN stock trade performance evaluation
Synthetic Biologics Inc. [SYN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -21.40. With this latest performance, SYN shares dropped by -28.27% in over the last four-week period, additionally plugging by 47.75% over the last 6 months – not to mention a rise of 38.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SYN stock in for the last two-week period is set at 31.91, with the RSI for the last a single of trading hit 25.65, and the three-weeks RSI is set at 36.54 for Synthetic Biologics Inc. [SYN]. The present Moving Average for the last 50 days of trading for this stock 0.6429, while it was recorded at 0.5173 for the last single week of trading, and 0.5601 for the last 200 days.
Synthetic Biologics Inc. [SYN]: An insightful look at the core fundamentals
Return on Total Capital for SYN is now -113.27, given the latest momentum, and Return on Invested Capital for the company is -87.12. Return on Equity for this stock declined to -89.69, with Return on Assets sitting at -78.32. When it comes to the capital structure of this company, Synthetic Biologics Inc. [SYN] has a Total Debt to Total Equity ratio set at 5.89. Additionally, SYN Total Debt to Total Capital is recorded at 5.56, with Total Debt to Total Assets ending up at 5.62.
Reflecting on the efficiency of the workforce at the company, Synthetic Biologics Inc. [SYN] managed to generate an average of -$1,004,300 per employee.Synthetic Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.
Earnings per share (EPS) analysis for Synthetic Biologics Inc. [SYN] stock
With the latest financial reports released by the company, Synthetic Biologics Inc. posted -0.2/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SYN.
Synthetic Biologics Inc. [SYN]: Insider Ownership positions
There are presently around $1 million, or 1.50% of SYN stock, in the hands of institutional investors. The top three institutional holders of SYN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,237,733, which is approximately 43.967% of the company’s market cap and around 1.77% of the total institutional ownership; FISHER ASSET MANAGEMENT, LLC, holding 127,698 shares of the stock with an approximate value of $65000.0 in SYN stocks shares; and BRIDGEWAY CAPITAL MANAGEMENT, LLC, currently with $55000.0 in SYN stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Synthetic Biologics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 14 institutional holders increased their position in Synthetic Biologics Inc. [AMEX:SYN] by around 574,550 shares. Additionally, 5 investors decreased positions by around 102,098 shares, while 10 investors held positions by with 1,229,132 shares. The mentioned changes placed institutional holdings at 1,905,780 shares, according to the latest SEC report filing. SYN stock had 8 new institutional investments in for a total of 178,112 shares, while 2 institutional investors sold positions of 94 shares during the same period.